OptimizeRx Appoints Microsoft Health & Life Sciences COO Mary Varghese Presti to Board, Expanding Strategic Expertise

summarizeSummary

OptimizeRx appointed Mary Varghese Presti, a Microsoft Health & Life Sciences COO, to its Board of Directors, bringing significant expertise in scaling healthcare technology and M&A integration to support the company's strategic growth initiatives.

check_boxKey Events

• New Independent Director Appointed

  Mary Varghese Presti, Corporate VP and COO of Microsoft's Health & Life Sciences, joined the Board on April 3, 2026.

• Board Expansion and Committee Role

  The Board expanded from six to seven members, and Ms. Presti was appointed to the Audit Committee.

• Strategic Expertise

  Ms. Presti brings over 25 years of experience in healthcare, life sciences, and technology, with a focus on scaling platforms, commercializing innovation, and M&A integration.

• Director Compensation

  Ms. Presti will receive an annual cash retainer of $45,000, an annual equity grant valued at approximately $175,000, and an additional $10,000 for Audit Committee service.

auto_awesomeAnalysis

OptimizeRx has strengthened its Board of Directors with the appointment of Mary Varghese Presti, a highly experienced executive from Microsoft's Health & Life Sciences organization. Her extensive background in scaling healthcare platforms, M&A integration, and driving operational efficiency at major technology and pharmaceutical companies is directly aligned with OptimizeRx's strategic objectives to evolve into a product-led platform with increasing recurring revenue. This appointment, which also expands the board and adds her to the Audit Committee, signals a proactive approach to enhancing governance and accelerating growth.